National Bank of Canada
SPRO icon

National Bank of Canada’s Spero Therapeutics SPRO Stock Holding History

National Bank of Canada’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$10.3K – 3137
2024
Q4 		$10.3K Hold
10,000
– – ﹤0.01% 2319
2024
Q3 		$13.4K Buy
+10,000
New +$13.4K ﹤0.01% 2016

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

National Bank of Canada's SPRO Position: Q1 2025 in Review

National Bank of Canada sold out of Spero Therapeutics (SPRO) in Q1 2025, closing a stake of 10,000 shares — an estimated $10.3K sold.

National Bank of Canada first reported a position in SPRO in Q3 2024 and held it in 2 quarters. The position peaked at $13.4K in Q3 2024. 38 funds tracked by Wall St. Rank hold SPRO as of Q1 2025.

  • National Bank of Canada reported no remaining Spero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • National Bank of Canada sold 10,000 Spero Therapeutics shares in Q1 2025, an estimated $10.3K.
  • National Bank of Canada first reported a position in Spero Therapeutics in Q3 2024 and held it in 2 quarters.
  • National Bank of Canada's Spero Therapeutics position peaked at $13.4K in Q3 2024.
  • 38 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2025.

Based on National Bank of Canada's 13F filing for Q1 2025, filed 12 May 2025.